Current Equity Capital 

 

As of June 2025, Stramsen Biotech Inc. boasts a robust equity capital structure designed to support its ambitious growth plans. The company has authorized 750 million shares, with approximately 229,041,217 shares currently outstanding. Based on the most recent valuation of $6.5 billion, our share price in the private market stands at approximately $28.38 per share. This valuation reflects the market's confidence in our innovative biotech solutions and potential for future growth.

​

Our substantial market capitalization and share structure provide us with the financial flexibility needed to pursue cutting-edge research and development initiatives. This strong financial foundation positions Stramsen Biotech Inc. to address critical challenges in the biotechnology and pharmaceutical sectors, ultimately contributing to the advancement of healthcare solutions and potential improvements in patient outcomes.

​

It's important to note that the information provided is accurate as of June 2025. However, given the dynamic nature of the biotech industry and financial markets, these figures may change. We are committed to transparency and will update this information regularly as needed. For the most current data regarding our outstanding shares or share price, please contact our investor relations team.

​

Our robust financial position enables us to tackle some of the most pressing issues in healthcare, including:

​

• Developing innovative treatments for rare diseases

• Advancing personalized medicine technologies

• Improving drug delivery systems for enhanced efficacy

• Exploring novel approaches to combat antibiotic resistance

By leveraging our strong capital structure, Stramsen Biotech Inc. is well-positioned to drive meaningful advancements in these areas, potentially revolutionizing patient care and addressing unmet medical needs on a global scale.

 

 

 

​

​